Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00065468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.
Study identification
- NCT ID
- NCT00065468
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 626 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2003 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Oct 25, 2012
2003 – 2011
United States locations
- U.S. sites
- 48
- U.S. states
- 28
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Little Rock | Arkansas | 72205 | — |
| Pfizer Investigational Site | La Verne | California | 91750 | — |
| Pfizer Investigational Site | Los Angeles | California | 90024-2828 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33428 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612-3824 | — |
| Pfizer Investigational Site | Urbana | Illinois | 61801 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46303 | — |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | — |
| Pfizer Investigational Site | Terre Haute | Indiana | 47802 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66160-7136 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70121 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21231-1000 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109-0942 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64131 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | Billings | Montana | 59101 | — |
| Pfizer Investigational Site | Great Falls | Montana | 59405 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03766 | — |
| Pfizer Investigational Site | East Orange | New Jersey | 07018 | — |
| Pfizer Investigational Site | Morristown | New Jersey | 07960 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | The Bronx | New York | 10466 | — |
| Pfizer Investigational Site | Valhalla | New York | 10595 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28602 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Pfizer Investigational Site | Portland | Oregon | 97213-2933 | — |
| Pfizer Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29414 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37920 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38120 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232-6310 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84112 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23249 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101 | — |
| Pfizer Investigational Site | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00065468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2012 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00065468 live on ClinicalTrials.gov.